A compound of formula, wherein •-R 1 is X 1, X 6, X 7, X 9 and X 10 are halogen, C 1 -C 4 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; X 2, X 3, X 4, X 5 and X 8, are hydrogen, halogen, C 1 -C 4 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; with the proviso that at least one of X 2, X 3, X 4, and X 5 is not hydrogen R 2 is a C 3 -C 6 linear branched or cyclic alkyl optionally substituted with phenyl, with one or more fluorine atoms or with trifluoromethyl-furanyl; R 2 ' is hydrogen, F, C 1 -C 3 linear or branched alkyl, or C 1 -C 3 linear or branched alkyl substituted with one or more fluorine atoms; or R 2 and R 2 ' together with the carbon atom they are attached to form a C 3 -C 6 cycloalkyl ring; •-R 3 is Y 1 is halogen; Y 1 ' is C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; Y 2 is cyano or methoxyphenyl, C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; Y 3 is hydrogen, halogen or methoxyphenyl; Y 4 is hydrogen, halogen, N-methylpyrazolyl, or a C 1 -C 3 linear branched or cyclic alkoxy optionally substituted with one or more fluorine atoms, Y 5 is hydrogen, halogen, cyano, or a C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; with the proviso that at least one of Y 4 and Y 5 is not hydrogen; Y 6 is halogen, C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms, or a C 1 -C 3 linear branched or cyclic alkoxy optionally substituted with one or more fluorine atoms; enantiomers, enantiomerically enriched mixtures, and pharmaceutically acceptable salts thereof. •-R 1 is X 1, X 6, X 7, X 9 and X 10 are halogen, C 1 -C 4 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; X 2, X 3, X 4, X 5 and X 8, are hydrogen, halogen, C 1 -C 4 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; with the proviso that at least one of X 2, X 3, X 4, and X 5 is not hydrogen R 2 is a C 3 -C 6 linear branched or cyclic alkyl optionally substituted with phenyl, with one or more fluorine atoms or with trifluoromethyl-furanyl; R 2 ' is hydrogen, F, C 1 -C 3 linear or branched alkyl, or C 1 -C 3 linear or branched alkyl substituted with one or more fluorine atoms; or R 2 and R 2 ' together with the carbon atom they are attached to form a C 3 -C 6 cycloalkyl ring; •-R 3 is Y 1 is halogen; Y 1 ' is C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; Y 2 is cyano or methoxyphenyl, C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; Y 3 is hydrogen, halogen or methoxyphenyl; Y 4 is hydrogen, halogen, N-methylpyrazolyl, or a C 1 -C 3 linear branched or cyclic alkoxy optionally substituted with one or more fluorine atoms, Y 5 is hydrogen, halogen, cyano, or a C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms; with the proviso that at least one of Y 4 and Y 5 is not hydrogen; Y 6 is halogen, C 1 -C 3 linear branched or cyclic alkyl optionally substituted with one or more fluorine atoms, or a C 1 -C 3 linear branched or cyclic alkoxy optionally substituted with one or more fluorine atoms; enantiomers, enantiomerically enriched mixtures, and pharmaceutically acceptable salts thereof.